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Abstract
Wilms’ tumors, or nephroblastomas, are thought to
arise from abnormal postnatal retention and dysregu-
lated differentiation of nephrogenic progenitor cells
that originate as a condensed metanephric mesen-
chyme within embryonic kidneys. We have previously
shown that the transcriptional regulator CITED1 (CBP/
p300– interacting transactivators with glutamic acid
[E ]/aspartic acid [D]–rich C-terminal domain) is ex-
pressed exclusively in these nephrogenic progenitor
cells and is downregulated as they differentiate to form
nephronic epithelia. In the current study, we show that
CITED1 expression persists in blastemal cell popula-
tions of both experimental rat nephroblastomas and
human Wilms’ tumors, and that primary human Wilms’
tumors presenting with disseminated disease show
the highest level of CITED1 expression. Unlike the
predominantly cytoplasmic subcellular localization
of CITED1 in the normal developing kidney, CITED1
is clearly detectable in the nuclear compartment of
Wilms’ tumor blastema. These findings indicate that
CITED1 is a marker of primitive blastema in Wilms’
tumors and suggest that persistent expression and/or
altered subcellular localization of CITED1 in the con-
densed metanephric mesenchyme could play a role
in Wilms’ tumor initiation and pathogenesis.
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Introduction
Wilms’ tumor, or nephroblastoma, is the most common
renal malignancy of childhood and is thought to arise from
alterations in the coordinated differentiation of nephrogenic
progenitor cells within the developing kidney. Normally,
nephrogenesis occurs as a result of reciprocal tissue inter-
actions between the ureteric bud (UB) epithelium, the
condensed metanephric mesenchyme surrounding UB tips,
and stromal mesenchyme [1,2]. These interactions coordi-
nate the differentiation of the condensed metanephric mes-
enchyme into epithelial elements that give rise to functional
adult nephrons. This process of mesenchymal-to-epithelial
transition occurs reiteratively throughout nephrogenesis and
is normally completed before birth in humans. Wilms’ tumors
typically comprise three cell types that are histologically remi-
niscent of those found in the developing kidney but that show
no functionally organized tissue architecture. These cellular
elements include undifferentiated blastema, primitive neph-
ronic epithelia, and stroma [3,4]. A significant subset of kidneys
from children who develop Wilms’ tumor contains putative pre-
cursor lesions, known as nephrogenic rests, that also manifest
histologic features of the condensed metanephric mesen-
chyme [5]. These observations have led to the hypothesis that
Wilms’ tumorigenesis is a result of abnormal postnatal reten-
tion and dysregulated differentiation of blastemal elements in
the developing kidney.
Aside from histologic similarities, the strongest evidence
supporting the embryonal origin of Wilms’ tumor stems from
early genetic studies that identified mutations in theWT1 gene
in 10% to 15% of patients who develop Wilms’ tumors [6].
These findings provide evidence of a link between Wilms’
tumorigenesis and defective embryonal development, as
WT1 is expressed in the developing kidney and plays a critical
role in nephrogenesis [7,8]. In addition, a number of global
gene array and expression studies have shown a significant
overlap between Wilms’ tumor and embryonic kidney gene
expression profiles [9–11]. In Wilms’ tumors, persistent ex-
pression of metanephric mesenchyme genes that are normally
downregulated in the adult kidney includes WT1 [12], PAX2
[13], SIX1, EYA1, SALL2, and HOXA11 [10]. However, there
exists no mouse model that recapitulates Wilms’ tumorigenesis
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de novo, precluding the use of mouse genetics to study
whether persistent expression of these embryonic genes
is necessary and/or sufficient to promote Wilms’ tumori-
genesis. The experimental model of Wilms’ tumor that best
mimics the histologic features of the human disease has
been established in newborn rats after transplacental de-
livery of the alkylating agent N-ethylnitrosourea (NEU) [14–
16]. These rats show a persistence of metanephric mesen-
chyme in the postnatal kidney that resembles nephrogenic
rests in humans and, after a latency of 4 to 8 months,
progresses to develop frank Wilms’ tumors associated
with typical triphasic cellular histology. Despite these obser-
vations, little progress has been made in understanding
neoplastic mechanisms that promote the persistence of
metanephric blastema and Wilms’ tumorigenesis.
Recent studies from our laboratory have characterized
the expression profile of the transcriptional regulator CITED1
(CBP/p300– interacting transactivators with glutamic acid
[E ]/aspartic acid [D]–rich C-terminal domain) during renal
development [17–19]. CITED1 is expressed at high levels
in the condensed metanephric mesenchyme surrounding
UB tips, is downregulated temporally as these cells begin
to differentiate into early epithelial structures, and is not
expressed in differentiated elements of the adult kidney
[19]. In the current study, we extend the embryonal charac-
terization of Wilms’ tumorigenesis by showing persistent
expression of CITED1 within the blastemal compartment of
both NEU-induced rat nephroblastomas and human Wilms’
tumors. We show that CITED1 expression in rat and human
nephroblastomas is associated with a shift in subcellular
localization from the cytoplasm in the condensed metaneph-
ric mesenchyme to the nucleus in tumor blastema, and that
the level of CITED1 expression in primary human Wilms’
tumors correlates with tumor stage at presentation. These
findings provide further evidence of the embryonal origin of
Wilms’ tumors and suggest that persistence and/or altered
subcellular localization of CITED1 in the blastema could play
a role in Wilms’ tumor initiation and pathogenesis.
Materials and Methods
Rat Wilms’ Tumor and Embryonic Kidney
To characterize the expression patterns of CITED1 in
Wilms’ tumor, we studied five experimental nephroblastomas
that were induced transplacentally after exposing Noble fetal
rats to N-nitroso-N-ethylurea, as described [16]. Briefly, at
17 days postcoitum (dpc), pregnant rats received an intra-
peritoneal injection of NEU (0.5 mmol/kg body weight). Dams
were allowed to deliver naturally and to nurse their offspring,
which were weaned and separated by sex at 4 weeks of age.
Rats were killed when tumors became palpable or when
animals became moribund. Tumor-bearing kidneys were
processed and paraffin-embedded for tissue analysis. Nor-
mal fetal rat kidneys not exposed to NEU were harvested at
16.5 dpc and processed similarly. Animal studies were
approved by the Institute for Animal Care and Use Com-
mittee of the National Cancer Institute.
Human Wilms’ Tumor and Embryonic Kidney
To characterize CITED1 expression patterns in human
Wilms’ tumor and to associate the CITED1 content of primary
tumors with stage of disease, risk for disease relapse, and
gender and age at presentation, we studied 20 favorable-
histology Wilms’ tumor (stages I–V) and 3 diffusely hyper-
plastic perilobar nephrogenic rest specimens (the typically
blastemal and epithelial precursor lesion of Wilms’ tumor;
we did not study the more stromal Wilms’ tumor precursor
intralobar nephrogenic rest) provided by the Children’s On-
cology Group (COG). To minimizeWilms’ tumor histology as a
confounding variable on disease relapse, we restricted our
studies to favorable-histology (no focal or diffuse anaplasia)
specimens, given the highly lethal and more unpredictable
biology of unfavorable-histology tumors. We received for-
malin-fixed paraffin-embedded histology slides and the
corresponding ‘‘snap-frozen’’ whole-tissue specimens pre-
pared from each of the 20 deidentified tumor patients. We
were blinded to all patient and specimen data until the studies
had been completed.
The COG chose 20 Wilms’ tumor specimens to compare
the CITED1 content of primary tumors among stage groups
and to assess whether CITED1 tumor content was different
in those patients who subsequently developed disease re-
lapse. Diagnostic tumor samples were chosen to include pa-
tients at all stages (stages I–V) [20] and to oversample
patients with disease relapse, as 10 of 20 patients whose
primary tumors were studied subsequently relapsed (Table 1).
This case–control-within-a-cohort study design permits the
assessment of relationships between CITED1 content and
patient characteristics, as well as the assessment of whether
CITED1 content is predictive of disease relapse risk.
Discarded human fetal kidneys, one each for gestational
ages 16 and 20 weeks, were procured from therapeutic
abortuses (Advanced Bioscience Resources, Inc., Alameda,
CA). Specimens were shipped overnight in sterile media on
ice and fixed immediately on arrival in 10% buffered formalin.
The Institutional Review Board of the Vanderbilt Univer-
sity School of Medicine approved all studies involving human
tumor and embryonic kidney specimens.
Immunohistochemistry and In Situ Hybridization
To characterize the cellular distribution of CITED1 in rat
and COG human specimens, we performed immunoperoxi-
dase staining of formalin-fixed paraffin-embedded tissues
(5-mm sections). Tissues were incubated overnight at 4jC
with affinity-purified rabbit anti-CITED1 antibody (1:50 dilu-
tion; LabVisionCorp., Fremont,CA).Goat–anti-rabbit second-
Table 1. Distribution of Human Wilms’ Tumor Samples, By Stage of Disease
at Presentation and By the Presence or Absence of Disease Relapse.
Stage I Stage II Stage III Stage IV Stage V Total
(N = 20)
Relapse-free 3 2 2 2 1 10
Relapse 2 2 2 3 1 10
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ary antibody (1:250 dilution; Santa Cruz Biotechnology,
Santa Cruz, CA) was applied to tissues at 37jC for 45 min-
utes, and tissues were visualized with a Vectastain ABC kit
(Vector Laboratories, Burlingame, CA). Immunofluores-
cence was used to characterize CITED1 subcellular locali-
zation, and the protocol parallels that of immunoperoxidase
staining by application of the secondary antibody. The TSA-
Plus Fluorescein Amplification System (PerkinElmer Life Sci-
ences, Boston, MA) was employed according to the manu-
facturer’s protocol, and nuclei were stained with TO- PRO-3
Nuclear Stain (Molecular Probes, Eugene, OR). Tumor spec-
imens were compared to embryonic kidneys for both rat and
human tissues.
Subcellular localization of CITED1 was characterized as
either predominantly cytoplasmic or mixed cytoplasmic and
nuclear for rat and human specimens using confocal micros-
copy at 630 original magnification (Carl Ziess, Thornwood,
NY; Cell Imaging Core, Vanderbilt University School of
Medicine). The intensity of CITED1 detection was scored
as absent, weak, intermediate, or strong by an independent
observer (M.W.) who was blinded to all specimen data.
Using in situ hybridization, we also screened rat and
human nephroblastomas for CITED1 mRNA to determine
whether increased CITED1 protein expression results directly
from dysregulated gene transcription. In situ hybridization was
performed as previously described [21], using 900-bp rat or
human CITED1 35S-radiolabeled antisense or control sense
probes on 10-mm sections of 4% buffered paraformaldehyde-
fixed paraffin-embedded rat or human tumor tissues, re-
spectively. For images of tumor tissues, dark-field emulsion
granules were converted to black and overlaid onto bright-
field images to yield a dark signal where CITED1 transcripts
were detected.
Protein Extraction and Quantification
To quantify CITED1 expression in each of the 20 snap-
frozen Wilms’ tumor samples provided by the COG and to
extract whole-tissue protein, specimens were homogenized
in lysis buffer containing protease inhibitors and sonicated
to disrupt cellular integrity, as described [22]. The protein
content of tissue lysates was determined after clarification
by Bradford assay, and an equivalent protein loading was
confirmed by Western blot analysis for b-actin (anti–b-actin
mouse monoclonal antibody; Sigma-Aldrich, St. Louis, MO).
To optimize CITED1 detection between samples, an equal
quantity of protein from each specimen was immunoprecipi-
tated using an affinity-purified rabbit anti-CITED1 antibody
raised against residues 178 to 193 of the CITED1 C-terminus,
as described [23]. Immunoprecipitates were then sepa-
rated by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, transferred to PVDF membranes, and probed with
the mouse MoAb anti-CITED1 antibody 2h6 [17,22]. To
estimate protein concentrations for each sample, CITED1
band intensities were quantified by densitometry (EpiChem3;
UVP Bioimaging System, Upland CA), and results were
normalized as the ratio of CITED1 to b-actin band densities
for each preparation.
Data Analysis
As the CITED1 content of primary human Wilms’ tumors
appeared to be normally distributed, we used linear regres-
sion methods to predict the mean CITED1 content as a func-
tion of stage and ‘‘relapse’’ status. After adjusting for the
differences in CITED1 levels seen by stage of disease
(stages I–III only), we further queried whether CITED1 con-
tent of primary tumors differed according to gender and age
at presentation. All statistical analyses were performed using
SAS (Cary, NC). Significant differences were determined for
P < .05. All data points were represented using box plots.
Results
CITED1 Expression in Rat Embryonic Kidneys
and Experimental Nephroblastomas
To characterize CITED1 expression patterns in embry-
onic and malignant blastemas, we initially analyzed rat
embryonic kidneys and NEU-induced nephroblastomas.
As expected in rat embryonic kidneys, CITED1 expression
is localized strictly to the condensed metanephric mesen-
chyme surrounding UB tips, and its expression is lost as
the condensed metanephric mesenchyme differentiates into
the earliest epithelial structure, the renal vesicle (Figure 1A)
[17]. The specificity of the antibody has been confirmed with
negative immunostaining in Cited1-null mutant mice that de-
velop normal aggregates of the condensed metanephric
mesenchyme and structural nephrons [19]. Using this same
antibody, we detected widespread CITED1 expression in
disorganized blastemal compartments of rat nephroblasto-
mas and no expression in primitive tubular, glomerular, or
stromal elements of these tumors (Figure 1B). In certain
tumor regions showing blastemal-to-epithelial transition,
CITED1 expression is strongest in peripheral blastema,
with absent or weak expression in the central more differen-
tiated tumor cells (Figure 1C, arrows).
We next performed immunofluorescence analysis to dis-
criminate carefully the subcellular localization of CITED1
within these two tissue types. As previously reported in
mouse embryonic kidneys [18,19], CITED1 is localized al-
most entirely to the cytoplasmic compartment of the con-
densed metanephric mesenchyme within rat embryonic
kidneys (Figure 2, A and B). In contrast, CITED1 is detect-
able in both the nuclear compartment and the cytoplasmic
compartment of blastemal cells in rat nephroblastomas
(Figure 2, C and D). In a count of 137 CITED1-positive meta-
nephric mesenchyme cells within rat embryonic kidneys
(n = 2), only 15 (10.9%) cells showed visible nuclear expres-
sion of CITED1, which was weak in intensity. In contrast, 359
of 434 (82.7%) CITED1-positive blastemal cells within rat
Wilms’ tumors (n = 2) showed a strong nuclear expression of
CITED1 (Figure 2E ).
CITED1 Expression in Human Embryonic Kidneys,
Wilms’ Tumors, and Perilobar Nephrogenic Rests
Having established the expression patterns of CITED1 in
rat embryonic kidneys and nephroblastomas, we proceeded
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to evaluate its expression in human tissue samples. CITED1
expression is restricted to the condensed metanephric mes-
enchyme of human embryonic kidneys of 16 and 20 weeks’
gestation (Figure 3, A and B), and it is highly expressed in
disorganized blastemal compartments of human Wilms’ tu-
mor samples (Figure 3, C and D). Unlike normal human
embryonic kidneys, CITED1 is detectable in primitive epithe-
lial structures in some (Figure 4), but not all (Figure 3D),
Wilms’ tumor samples. Rare primitive tubular structures in
the form of rosettes show an intermediate intensity of CITED1
expression (Figure 4A), yet more mature-appearing epithe-
lial structures show a weak and cytoplasmic expression of
CITED1 (Figure 4B). As in the rat nephroblastoma model
(Figure 1C), certain human tumor regions show a CITED1
expression gradient from greater intensity in peripheral blas-
temal cells (also lacking organized architecture) to weak cyto-
plasmic expression in the more organized tubular portion
(Figures 3D and 4C). Semiquantitative evaluation of the
20 COG human WTsamples showed that 13 of 15 mixed tu-
mor types displayed weak or intermediate staining of CITED1
in primitive epithelial structures (Table 2).
Consistent with data in rat embryonic kidneys and ex-
perimental nephroblastomas, confocal imaging of CITED1
expression confirmed dominant cytoplasmic localization in
the condensed metanephric mesenchyme of the human
embryonic kidney, whereas CITED1 was clearly detected in
the nuclear and cytoplasmic compartments of blastemal cells
within human WT samples (Figure 5). Immunofluorescent
staining of human fetal kidneys shows that CITED1 expres-
sion is restricted to the condensed metanephric mesenchyme
and is localized predominantly to the cytoplasm of this pro-
genitor cell population (Figure 5A). CITED1 expression is in-
tense in malignant blastema and, in contrast to the embryonic
state, is robustly detected in the nuclei of this transformed
cell population (Figure 5, B and C). Aggregation and differen-
tiation of blastema show downregulation of CITED1 expres-
sion relative to disorganized blastema (Figure 5B).
Of the 20 COG Wilms’ tumor tissue sections, areas of
blastemal and epithelial elements were present in 17 and
13 samples, respectively—sufficient to perform a detailed
evaluation of CITED1 immunostaining in these cellular sub-
types (Table 2). Disorganized blastemal regions in each tumor
(100%) showed nuclear CITED1 localization of variable in-
tensity. In contrast, primitive epithelia in 3 of 13 (23%) tumors
showed CITED1 nuclear expression, yet more organized epi-
thelia in the remaining 10 tumors showed variable intensity
of CITED1 expression restricted to the cytoplasm. Seven of
17 (41%) tumors having sufficient blastema showed strong
CITED1 nuclear expression in disorganized blastemal
regions, whereas only 1 of 13 (8%) tumors having sufficient
epithelia showed strong CITED1 nuclear expression within
epithelial elements. Interestingly, the COG had classified this
latter tumor as ‘‘epithelial undifferentiated.’’
Immunostaining of perilobar nephrogenic rests, which are
considered neoplastic precursors of Wilms’ tumor, showed a
similar pattern of mixed nuclear and cytoplasmic staining in
the blastema, with weak cytoplasmic staining in associated
epithelial, but not stromal, structures (Figure 6).
Figure 1. CITED1 immunoperoxidase staining (brown) of rat fetal kidney (A)
and NEU-induced nephroblastoma (B and C). (A) CITED1 expression in rat
fetal kidney (FK) 16.5 dpc is restricted to the condensed metanephric
mesenchyme (CM) immediately adjacent to and surrounding UB tubular
structures (original magnification, 400). Note the absence of CITED1
expression in the early renal vesicle (RV) epithelia of mesenchymal origin. (B)
CITED1 expression in rat nephroblastoma (WT) is intense in blastemal
elements (brown) and absent in primitive epithelia (white arrows, tubules;
black arrowhead, glomerulus) and stroma (St) (original magnification, 400).
(C) The region of blastemal-to-epithelial transition shows downregulation of
CITED1 expression in a gradient from positive peripheral blastema to
negative central epithelia (arrows) (original magnification, 200).
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Figure 2. CITED1 immunofluorescent staining (green) of rat fetal kidney (rows A and B) and NEU-induced nephroblastoma (rows C and D). TO-PRO3 nuclear
stain appears red. (A) Original magnification, 200; (B) original magnification, 400. (A and B) CITED1 is detected predominantly in the cytoplasm of the
condensed metanephric mesenchyme in rat fetal kidneys (FK) 16.5 dpc, whereas in rat Wilms’ tumor (WT), CITED1 is richly detected in the nuclear and
cytoplasmic compartments. (C) Original magnification, 400; (D) original magnification, 630. (E) In cells expressing CITED1, rat WT showed markedly greater
and more visible nuclear accumulation than the condensed metanephric mesenchyme.
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Figure 3. CITED1 immunoperoxidase staining of human fetal kidney (A and B) and Wilms’ tumors (C and D). (A) Original magnification, 100; (B) original
magnification, 400. (A and B) As in the rat fetal kidney, CITED1 expression is restricted to the condensed metanephric mesenchyme (CM) immediately adjacent
to and surrounding the UB. (B) The earliest epithelial structures of mesenchymal origin, pretubular aggregates (*), and renal vesicles (RV) again show the absence
of CITED1 expression in the human fetal kidney. (C) CITED1 expression is intense in malignant blastema (Bl) but absent in stroma (St) (original magnification,
100). (D) The region of blastemal-to-epithelial transition in human Wilms’ tumor also shows a gradient of CITED1 expression from intense in peripheral blastema
to absent in central epithelia (Ep) (original magnification, 400).
Figure 4. CITED1 expression was detected in certain primitive epithelial structures of human Wilms’ tumors. (A) Primitive tubular structures in the form of rosettes
show CITED1 expression (white arrows) (original magnification, 200). (B) A more mature-appearing epithelial structure shows a weak cytoplasmic expression of
CITED1 (black arrow) (original magnification, 400). (C) CITED1 expression in certain tumor regions shows an intensity gradient from greater cytoplasmic
expression in peripheral blastemal cells (also lacking organized architecture) to weak cytoplasmic expression in the more organized tubular portion (black arrow)
(original magnification, 400). (D) Primitive tubules and epithelial elements showing intermediate CITED1 expression (original magnification, 400).
594 CITED1 Expression in Wilms’ Tumor Lovvorn et al.
Neoplasia . Vol. 9, No. 7, 2007
Table 2. Intensity and Subcellular Localization of CITED1 in Blastemal or Epithelial Elements, Arranged in Ascending Order of Disease Stage.




Nucleus Cytoplasm Nucleus Cytoplasm
Pathology of Specimen
Received
I 73.9193 Mixed Intermediate Intermediate Absent Weak
I 142.956 Mixed Weak Intermediate Blastemal predominant
I 161.329 Mixed Weak Strong Absent Intermediate
I 175.217 Mixed Strong Intermediate Absent Weak
I 225.351 Epithelial undifferentiated Strong Intermediate Epithelial predominant
II 97.6555 Mixed Absent Intermediate Epithelial predominant
II 136.057 Mixed Intermediate Intermediate Absent Weak
II 190.715 Blastemal Intermediate Strong Blastemal predominant
II 197.219 Mixed Intermediate Intermediate Absent Weak
III 93.3567 Mixed Weak Strong Absent Intermediate
III 104.387 Mixed Intermediate Intermediate Blastemal predominant
III 180.112 Mixed Strong Intermediate Weak Intermediate
III 220.589 Mixed Strong Intermediate Blastemal predominant
IV 223.771 Mixed Weak Strong Weak Intermediate
IV 236.798 Mixed Absent Intermediate Epithelial predominant
IV 241.154 Blastemal Intermediate Strong Blastemal predominant
IV 241.407 Blastemal Strong Intermediate Blastemal predominant
IV 300.985 Blastemal Strong Strong Blastemal predominant
V 158.057 Mixed Strong Intermediate Absent Weak
V 299.851 Mixed Strong Strong Absent Weak
Figure 5. CITED1 immunofluorescent staining of human fetal kidney (FK; row A) and Wilms’ tumor (WT; rows B and C). CITED1 and TO-PRO3 nuclear stain are
represented in green and red, respectively. (Row A) CITED1 expression is restricted to the condensed metanephric mesenchyme (CM) and is localized pre-
dominantly in the cytoplasm (white arrows) (original magnification, 630). (Rows B and C) CITED1 expression is intense in malignant blastema and, in contrast to
the embryonic state, is robustly detected in the nuclei of this cell population. (B) Aggregating and differentiating blastema (*) show downregulation of CITED1
expression relative to surrounding disorganized blastemas (bright green; Ep = epithelia) (original magnification, 400). (C) High-power view of malignant blastema
showing a rich nuclear accumulation of CITED1 (Ep = epithelia) (original magnification, 630).
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To confirm these immunohistochemical analyses, we also
performed in situ hybridization to evaluate CITED1 mRNA
expression in experimental rat and human Wilms’ tumors.
As shown in Figure 7, high levels of CITED1 mRNA were
restricted to blastemal elements of both rat and human
nephroblastomas. Analogous to protein expression studies,
CITED1 mRNA was not detected in epithelial or stromal
elements of the tumors examined.
CITED1 Content in Primary Human Wilms’ Tumors
and Stage of Disease
We compared CITED1 expression in the 20 COG Wilms’
tumor samples to determine whether its cellular distribution
or subcellular localization varied among tumor stages I to V.
Wilms’ tumor stage is a clinical variable based on tumor
volume and spread, and it is not influenced by the histologic
appearance of tumors [24]. In our studies, CITED1 was
widely expressed in all tumor stages, yet showed the stron-
gest immunostaining within blastemal compartments of
higher stage malignancies (stages III–V; Table 2). Further-
more, in localized disease stages I and II (n = 9), CITED1
showed strong nuclear expression in only two specimens,
whereas in more advanced stages (stages III–V), nuclear
expression of CITED1 was characterized as strong in 6 of 11
tissue samples (Table 2).
To further evaluate these immunohistochemical observa-
tions, we quantified CITED1 protein expression in all 20 COG
Wilms’ tumor samples by Western blot analysis. Despite the
Figure 6. CITED1 expression in human perilobar nephrogenic rests (PLNRs). (A) Immunoperoxidase staining shows that CITED1 expression is rich in blastemal
structures (*) but absent in stroma (St) (original magnification, 200). (B) Intensity gradient of CITED1 expression from strong in peripheral undifferentiated
blastema to reduced or absent in clearly defined tubular elements (black arrow) (original magnification, 200). (C) Variable cytoplasmic and nuclear localizations of
CITED1 in blastemal elements (original magnification, 630).
Figure 7. In situ hybridization detects CITED1 mRNA in rat (A) and human (B–D) nephroblastoma (WT). (A) Rat WT shows that CITED1 mRNA is restricted to
blastemal compartments (Bl; dark regions). CITED1 mRNA is also detected in peripheral blastema (arrows) immediately surrounding more differentiated tumor
epithelia (Ep). Epithelial and stromal (St) compartments do not express CITED1 mRNA. (B) Human WT shows CITED1 mRNA restriction to blastemal
compartments (Bl; dark regions) and absence in stroma (St). (C) Epithelial-predominant human WT showing no detection of CITED1 mRNA in either epithelia (Ep)
or stroma (St). (D) Sense control showing no detection of radiolabeled probe.
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strong blastemal immunostaining noted above, initial experi-
ments performed to detect CITED1 expression in whole
tumor lysates failed, presumably the result of diluting total
protein from CITED1-expressing cells with other nonex-
pressing cellular elementswithin tumors (epithelia and stroma).
We therefore enriched the CITED1 content of tumor lysates
by immunoprecipitation using an anti-CITED1 antibody
(Figure 8). As shown in Figure 8, several Wilms’ tumor speci-
mens express a CITED1 doublet that likely reflects protein
phosphorylation—a posttranslational modification that we
have demonstrated as occurring in proliferating cells [18].
Compared to patients presenting with disease at stages I
to III, patients with metastatic stage IV disease (n = 5) at
diagnosis had significantly greater CITED1 protein content in
primary tumors (P = .0033; Figure 9A). The two specimens
obtained from patients presenting with bilateral stage V
disease also had a higher mean CITED1 protein content in
primary tumors, but this difference did not reach statistical
significance possibly because of low numbers assayed from
this stage (P = .08). Notably, we did not receive any further
substaging criteria for these two stage V tumors. However,
after adjusting for the differences in CITED1 protein content
seen by disease stage, CITED1 content in primary Wilms’
tumors was not different between patients who developed
disease relapse and those who did not (P = .88). A review of
tumor sample histology did not associate the greater CITED1
protein content with blastemal predominance of stage IV
tumors. This observation suggests that the increased ex-
pression of CITED1 in stage IV tumors does not simply result
from increased numbers of blastemal cells, but that CITED1
expression is upregulated in malignant blastema.
Exploratory data analysis showed further that the CITED1
protein content of primary Wilms’ tumors appeared to associ-
ate with the gender and age of a child at presentation for
patients with localized disease (stages I–III). After adjusting
for differences in CITED1 protein content according to dis-
ease stage, the CITED1 content of primary tumors for fe-
males aged > 4 years (n = 4) was greater than that for all other
gender–age groups presenting with nonmetastatic disease
(Figure 9B). Regression analysis showed that CITED1 values
for females aged > 4 years were significantly greater (P =
.003) than those for females presenting at < 4 years (n = 4) or
for any aged male (n = 5), and that these values approached
those for patients presenting with metastatic disease.
Discussion
In these studies, we have characterized for the first time the
blastemal expression of the transcriptional regulator CITED1
in human and NEU-induced rat Wilms’ tumors. Our findings
demonstrate that CITED1 is consistently expressed in dis-
organized blastemal cells of both human and experimental
Wilms’ tumors and of the putative precursor lesions, peri-
lobar nephrogenic rests. We show further that CITED1 is
clearly detected in the nuclear compartment of transformed
blastema relative to its predominantly cytoplasmic localiza-
tion in embryonic metanephric mesenchyme. Interestingly,
in both human and rat tumors, CITED1 is expressed most
Figure 8. Representative Western blot analysis for CITED1 after immunoprecipitation (IP). (A) -Actin control Western blot analysis of tissue lysates performed to
confirm that equal quantities of sample protein were immunoprecipitated for CITED1. (B) CITED1 (C1) bands after initial immunoprecipitation using a rabbit anti-
CITED1 antibody, and subsequent Western blot analysis (WB) using the mouse anti-CITED1 monoclonal antibody 2h6. CITED1 migrates as a doublet in several
WT specimens. The MCF-7 breast carcinoma cell line served as a CITED1-positive control [18]. Rabbit IgG was used as a negative control for
immunoprecipitation. WT-5 and WT-7 represent different Wilms’ tumor samples expressing different quantities of CITED1.
Figure 9. (A) The CITED1 protein content of primary Wilms’ tumors, as estimated by the ratio of Western blot optical densities of specimen CITED1 to -actin
bands (vertical axis), was associated with advanced stage IV disease. The total number of patients per stage and the absolute values of CITED1 content per tumor
are shown in Table 2. The CITED1 content of primary stage IV tumors was compared to that for stages I to III. *P = .0033. (B) CITED1 protein content was also
highest in the primary Wilms’ tumors of girls presenting beyond 4 years of age. The CITED1 content of primary WT arising in girls aged > 4 years (n = 4) was
compared to that arising in girls presenting at < 4 years (n = 4) or to that arising in boys at any age (n = 5). *P = .003.
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intensely along the outer cells of undifferentiated blastema
that surround aggregates of more differentiated elements.
Finally, we have shown that the level of CITED1 expres-
sion in primary Wilms’ tumors correlates with tumor stage.
Taken together, these observations are consistent with the
hypothesis that Wilms’ tumor blastema are derived from the
abnormal postnatal retention of the condensed metanephric
mesenchyme within the adult kidney, and establish CITED1
as a new histologic marker of malignant blastema. Further-
more, the correlation of our human tumor findings with
chemically induced rat nephroblastomas confirms that the
latter is a good model of the human disease.
The highest expression levels of CITED1 were detected
in primary Wilms’ tumors of children presenting with ad-
vanced stage IV disease, implicating this transcriptional
regulator as a marker of disease severity. Other cell-based
and tumor-based markers, including telomerase [25], IGFR-I
[26], topoisomerase II [27], and CRABP2 [28,29], have been
associated with adverseWilms’ tumor behaviors; in a hetero-
transplant model of human Wilms’ tumor, increasing serum
hyaluronan concentrations have been associated with more
aggressive Wilms’ tumor biology [30]. None of these factors,
however, has been clearly associated with the cellular func-
tion of embryonic condensed metanephric mesenchyme.
Previous microarray studies have shown that a number of
genes involved in nephrogenesis, yet normally downregu-
lated in the adult kidney, are overrepresented inWilms’ tumor
specimens. These metanephric mesenchyme genes include
WT1 [12], PAX2 [13], SIX1, EYA1, SALL2, and HOXA11
[10]. However, these studies do not establish the precise
cellular distribution or regulation of gene expression, either
within the tumors themselves or in different tumor stages.
Using a highly specific and commercially available anti-
CITED1 antibody, we have been able to map carefully the
expression of this developmentally regulated protein in em-
bryonal Wilms’ tumors. Our observation that CITED1 shows
a gradient of expression (highest in the outer cells of blas-
temal compartments that surround histologically more differ-
entiated, CITED1-negative tumor elements) provides the first
evidence that this population of undifferentiated cells may be
undergoing progressive epithelial transition. This pattern of
differentiation caricatures the normal induction of the con-
densed metanephric mesenchyme within the developing
kidney and suggests that active inductive signaling modifies
the cellular composition of Wilms’ tumors. Unlike the devel-
oping kidney, however, CITED1 is detected in primitive tumor
epithelia, suggesting further that these cells may represent
an intermediate embryonic phenotype not normally seen in
development. In contrast, the observation that CITED1 is
never detected in stromal elements suggests that the ontog-
eny of this cell population is distinct from blastemal and
epithelial elements in Wilms’ tumors.
Altered subcellular localization of CITED1 in Wilms’ tu-
mors was an unexpected finding and suggests that its
regulation could play a role in Wilms’ tumor initiation and
pathogenesis. Distinct from the dominant cytoplasmic locali-
zation of CITED1 in the condensed metanephric mesen-
chyme, CITED1 is equally distributed between the nuclear
compartment and the cytoplasmic compartment of Wilms’
tumor blastema. This phenomenon is also seen in diffusely
hyperplastic perilobar nephrogenic rests containing prema-
lignant Wilms’ tumor precursor cells, indicative that change
in the subcellular localization of CITED1 occurs early in the
course of the disease. We have previously shown that
CITED1 contains a strong nuclear export signal within its
C-terminal transactivation domain [18]. The mixed nuclear–
cytoplasmic distribution of CITED1 in Wilms’ tumors is
consistent with loss of nuclear export signal function, but
how this mechanism is perturbed in malignant cells remains
unknown. Interestingly, the related family member CITED4
has been shown to shift from a predominantly nuclear locali-
zation to the cytoplasm during the transformation of normal
tissue to malignant breast tissue [31], suggesting a possible
conservation of mechanisms regulating subcellular localiza-
tion in this family of proteins and contributing to neoplasia.
Our in situ hybridization data support the concept that
CITED1 gene transcription is dysregulated in Wilms’ tumor
pathogenesis, yet its functional contributions to nephroblas-
toma initiation and progression remain unclear. High levels of
CITED1 expression could simply be a marker of blastemal
persistence in these tumors; however, our studies show that
the level of CITED1 expression correlates with tumor stage
independently of blastemal content in Wilms’ tumors, sug-
gesting a direct role for CITED1 in Wilms’ tumor progression.
Additionally, the observation that CITED1 is localized to the
nucleus of blastema within the precursor lesions, nephro-
genic rests, implicates a further role inWilms’ tumor initiation.
There exist two alternative mechanisms, although not nec-
essarily mutually exclusive, by which CITED1 could influ-
ence Wilms’ tumorigenesis. First, high cellular levels of
CITED1 could exert a direct oncogenic effect on blastemal
cells. This explanation is supported by the observation that
high levels of CITED1 have been associated not only with
Wilms’ tumors but also with malignancies of the thyroid gland
[32], and skin [33]. Furthermore, we have shown that over-
expression of CITED1 in the human Wilms’ tumor cell line
SK-NEP-1 enhances cellular proliferation in vitro, whereas
overexpression of a truncated functionally inactive CITED1
mutant perturbs this effect in vitro and tumorigenesis in vivo
[22]. As SK-NEP-1 cells have not been shown to differenti-
ate or to form epithelial structures in heterotransplant mod-
els, it is likely that overexpression of this dominant-negative
CITED1 mutant modifies SK-NEP-1 tumorigenesis by per-
turbing cellular proliferative capacity and survival more than
inducing cellular differentiation.
A second possible mechanism is that persistent expres-
sion of CITED1 in metanephric blastema could play an ad-
verse developmental role in the pathogenesis of these
tumors. We have previously shown that overexpression of
CITED1 in cultured embryonic kidneys interferes with orga-
nized differentiation of the condensed metanephric mesen-
chyme [17]. This observation suggests that dysregulated
CITED1 expression could play a role in preventing the or-
ganized differentiation of the metanephric mesenchyme,
thereby promoting the persistence of metanephric blastema
in postnatal kidneys of Wilms’ tumor patients. This hypoth-
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esis is consistent with the observation that CITED1 over-
expression inhibits Wnt/b-catenin–dependent transcriptional
responses [17], as Wnt signaling promotes epithelial differ-
entiation of the metanephric mesenchyme in vivo [34,35].
Indeed, activating mutations of b-catenin have been de-
scribed in 10% to 15% of Wilms’ tumors [36–38]. Subse-
quent evidence that an even higher percentage of sporadic
Wilms’ tumors shows stabilization and nuclear accumulation
of b-catenin has emerged [39]. Furthermore, more recent
studies have identified inactivating mutations in the X-linked
gene WTX in 30% of Wilms’ tumors [40], and WTX is an
essential component of the b-catenin destruction complex
[41]. These findings raise the possibility that increased levels
of CITED1 expression in metanephric blastema could play a
role in preventing Wnt-dependent epithelial differentiation in
established Wilms’ tumors.
Finally, the primary tumors of girls aged > 4 years showed
the highest CITED1 protein content, which is of interest
because the gene locus for CITED1 is found on the X chro-
mosome [42]. Furthermore, CITED1 has been shown to
function as a selective coactivator of estrogen-dependent
transcription [43]. In a recent Danish population-based study,
investigators showed that the risk of developing Wilms’ tumor
increased with excessive fetal growth in girls and decreased
with fetal growth in boys, although the findings did not reach
statistical significance [44]. Nevertheless, we do not know
the serum estrogen content of the patients in our study, nor
do we understand the functional significance of CITED1 and
estrogen interactions in Wilms’ tumor pathogenesis. The in-
fluence of maternal estrogen on the persistence of embryonic
blastemal elements remains only speculative.
In summary, we have characterized the expression pat-
terns of CITED1 in two models of nephroblastoma. We have
shown that CITED1, which is normally expressed in the con-
densed metanephric mesenchyme and downregulated in the
postnatal kidney, persists as a marker of blastema cells in
both premalignant nephrogenic rests and malignant Wilms’
tumors. Furthermore, our studies show that CITED1 local-
izes to the nucleus of Wilms’ tumor blastema and that the
level of CITED1 expression in the transformed blastema of
primary human Wilms’ tumors correlates with the stage of the
disease. These findings indicate that CITED1 is a novel marker
of Wilms’ tumor blastema and suggest that persistent expres-
sion and/or altered subcellular localization of CITED1 could
play a role in the initiation and pathogenesis of Wilms’ tumors.
Acknowledgements
The authors thank Toshi Shioda for graciously providing the
anti-CITED1 antibody 2h6. We also are indebted to Jeffrey
Dome and the COG for providing human Wilms’ tumor speci-
mens and insightful assistance with this study.
References
[1] Saxen L and Sariola H (1987). Early organogenesis of the kidney.
Pediatr Nephrol 1, 385–392.
[2] Dressler GR (2006). The cellular basis of kidney development. Annu
Rev Cell Dev Biol 22, 509–529.
[3] Beckwith JB (1997). New developments in the pathology of Wilms
tumor. Cancer Invest 15, 153–162.
[4] Schmidt D and Beckwith JB (1995). Histopathology of childhood renal
tumors. Hematol/Oncol Clin North Am 9, 1179–1200.
[5] Beckwith JB, Kiviat NB, and Bonadio JF (1990). Nephrogenic rests,
nephroblastomatosis, and the pathogenesis of Wilms’ tumor. Pediatr
Pathol 10, 1 –36.
[6] Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL,
Douglass EC, and Housman DE (1990). An internal deletion within
an 11p13 zinc finger gene contributes to the development of Wilms’
tumor. Cell 61, 1257–1269.
[7] Bruening W, Bardeesy N, Silverman BL, Cohn RA, Machin GA, Aronson
AJ, Housman D, and Pelletier J (1992). Germline intronic and exonic
mutations in the Wilms’ tumour gene (WT1) affecting urogenital devel-
opment. Nat Genet 1, 144–148.
[8] Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D,
and Jaenisch R (1993). WT-1 is required for early kidney development.
Cell 74, 679–691.
[9] Li W, Kessler P, and Williams BR (2005). Transcript profiling of Wilms
tumors reveals connections to kidney morphogenesis and expression
patterns associated with anaplasia. Oncogene 24, 457–468.
[10] Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R,
Klein U, and Tycko B (2002). Gene expression in Wilms’ tumor mim-
ics the earliest committed stage in the metanephric mesenchymal –
epithelial transition. Am J Pathol 160, 2181–2190.
[11] Dekel B, Metsuyanim S, Schmidt-Ott KM, Fridman E, Jacob-Hirsch J,
Simon A, Pinthus J, Mor Y, Barasch J, Amariglio N, et al. (2006). Multi-
ple imprinted and stemness genes provide a link between normal and
tumor progenitor cells of the developing human kidney. Cancer Res 66,
6040–6049.
[12] Grubb GR, Yun K, Williams BR, Eccles MR, and Reeve AE (1994).
Expression of WT1 protein in fetal kidneys and Wilms tumors. Lab
Invest 71, 472–479.
[13] Dressler GR and Douglass EC (1992). Pax-2 is a DNA-binding protein
expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci
USA 89, 1179–1183.
[14] Sharma PM, Bowman M, Yu BF, and Sukumar S (1994). A rodent
model for Wilms tumors: embryonal kidney neoplasms induced by N-
nitroso-N V-methylurea. Proc Natl Acad Sci USA 91, 9931–9935.
[15] Hard GC (1985). Differential renal tumor response to N-ethylnitrosourea
and dimethylnitrosamine in the Nb rat: basis for a new rodent model of
nephroblastoma. Carcinogenesis 6, 1551–1558.
[16] Higinbotham KG, Karavanova ID, Diwan BA, and Perantoni AO (1998).
Deficient expression of mRNA for the putative inductive factor bone
morphogenetic protein-7 in chemically initiated rat nephroblastomas.
Mol Carcinog 23, 53–61.
[17] Plisov S, Tsang M, Shi G, Boyle S, Yoshino K, Dunwoodie SL, Dawid IB,
Shioda T, Perantoni AO, and de Caestecker MP (2005). Cited1 is a
bifunctional transcriptional cofactor that regulates early nephronic pat-
terning. J Am Soc Nephrol 16, 1632–1644.
[18] Shi G, Boyle SC, Sparrow DB, Dunwoodie SL, Shioda T, and de
Caestecker MP (2006). The transcriptional activity of CITED1 is regu-
lated by phosphorylation in a cell cycle–dependent manner. J Biol
Chem 281, 27426–27435.
[19] Boyle SC, Shioda T, Perantoni AO, and de Caestecker MP (2007).
Cited1 and Cited2 are differentially expressed in the developing kidney
but are not required for nephrogenesis. Dev Dyn [Epub July 5].
[20] Green DM (1997). Wilms’ tumour. Eur J Cancer 33, 409–418, discus-
sion, 419–420.
[21] Perantoni AO, Timofeeva O, Naillat F, Richman C, Pajni-Underwood S,
Wilson C, Vainio S, Dove LF, and Lewandoski M (2005). Inactivation of
FGF8 in early mesoderm reveals an essential role in kidney develop-
ment. Development 132, 3859–3871.
[22] Lovvorn HN III, Boyle S, Shi G, Shyr Y, Wills ML, Perantoni AO, and
de Caestecker M (2007). Wilms’ tumorigenesis is altered by misexpression
of the transcriptional co-activator, CITED1. J Pediatr Surg 42, 474–481.
[23] Shioda T, Fenner MH, and Isselbacher KJ (1996). msg1, a novel mela-
nocyte-specific gene, encodes a nuclear protein and is associated with
pigmentation. Proc Natl Acad Sci USA 93, 12298–12303.
[24] Green DM (2004). The treatment of stages I– IV favorable histology
Wilms’ tumor. J Clin Oncol 22, 1366–1372.
[25] Dome JS, Bockhold CA, Li SM, Baker SD, Green DM, Perlman EJ, Hill
DA, and Breslow NE (2005). High telomerase RNA expression level is
an adverse prognostic factor for favorable-histology Wilms’ tumor. J Clin
Oncol 23, 9138–9145.
[26] Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler MA, Dome
JS, Grundy PE, Vujanic GM, Pritchard-Jones K, and Jones C (2006).
CITED1 Expression in Wilms’ Tumor Lovvorn et al. 599
Neoplasia . Vol. 9, No. 7, 2007
Blastemal expression of type I insulin-like growth factor receptor in
Wilms’ tumors is driven by increased copy number and correlates with
relapse. Cancer Res 66, 11148–11155.
[27] Tretiakova M, Turkyilmaz M, Grushko T, Kocherginsky M, Rubin C, Teh
B, and Yang XJ (2006). Topoisomerase IIalpha in Wilms’ tumour: gene
alterations and immunoexpression. J Clin Pathol 59, 1272–1277.
[28] Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick
K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, et al.
(2006). Array CGH profiling of favourable histology Wilms tumours re-
veals novel gains and losses associated with relapse. J Pathol 210,
49–58.
[29] Takahashi M, Yang XJ, Lavery TT, Furge KA, Williams BO, Tretiakova
M, Montag A, Vogelzang NJ, Re GG, Garvin AJ, et al. (2002). Gene
expression profiling of favorable histology Wilms tumors and its corre-
lation with clinical features. Cancer Res 62, 6598–6605.
[30] Lovvorn HN III, Savani RC, Ruchelli E, Cass DL, and Adzick NS (2000).
Serum hyaluronan and its association with unfavorable histology and
aggressiveness of heterotransplanted Wilms’ tumor. J Pediatr Surg 35,
1070–1078.
[31] Fox SB, Braganca J, Turley H, Campo L, Han C, Gatter KC, Bhattacharya
S, and Harris AL (2004). CITED4 inhibits hypoxia-activated transcription
in cancer cells, and its cytoplasmic location in breast cancer is associated
with elevated expression of tumor cell hypoxia-inducible factor 1alpha.
Cancer Res 64, 6075–6081.
[32] Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y, and de la
Chapelle A (2004). CITED1 protein expression suggests papillary
thyroid carcinoma in high throughput tissue microarray-based study.
Thyroid 14, 169–175.
[33] Li H, Ahmed NU, Fenner MH, Ueda M, Isselbacher KJ, and Shioda T
(1998). Regulation of expression of MSG1 melanocyte-specific nu-
clear protein in human melanocytes and melanoma cells. Exp Cell
Res 242, 478–486.
[34] Carroll TJ, Park JS, Hayashi S, Majumdar A, and McMahon AP (2005).
Wnt9b plays a central role in the regulation of mesenchymal to epithelial
transitions underlying organogenesis of the mammalian urogenital sys-
tem. Dev Cell 9, 283–292.
[35] Kispert A, Vainio S, and McMahon AP (1998). Wnt-4 is a mesenchymal
signal for epithelial transformation of metanephric mesenchyme in the
developing kidney. Development 125, 4225–4234.
[36] Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F,
Briner J, and von Knebel Doeberitz M (1999). Mutational activation
of the beta-catenin proto-oncogene is a common event in the develop-
ment of Wilms’ tumors. Cancer Res 59, 3880–3882.
[37] Maiti S, Alam R, Amos CI, and Huff V (2000). Frequent association of
beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 60,
6288–6292.
[38] Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW,
Murty VV, Grundy PE, Fearon ER, et al. (2004). CTNNB1 mutations
and overexpression of Wnt/beta-catenin target genes in WT1-mutant
Wilms’ tumors. Am J Pathol 165, 1943–1953.
[39] Koesters R, Niggli F, von Knebel Doeberitz M, and Stallmach T (2003).
Nuclear accumulation of beta-catenin protein in Wilms’ tumours. J Pathol
199, 68–76.
[40] Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim
JC, Feinberg AP, Gerald WL, Vargas SO, et al. (2007). An X chromo-
some gene, WTX, is commonly inactivated in Wilms tumor. Science
315, 642–645.
[41] Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C,
Biechele TL, Gingras AC, Zheng N, Maccoss MJ, et al. (2007). Wilms
tumor suppressor WTX negatively regulates WNT/beta-catenin signal-
ing. Science 316, 1043–1046.
[42] Fenner MH, Parrish JE, Boyd Y, Reed V, MacDonald M, Nelson DL,
Isselbacher KJ, and Shioda T (1998). MSG1 (melanocyte-specific gene
1): mapping to chromosome Xq13.1, genomic organization, and pro-
moter analysis. Genomics 51, 401–407.
[43] Yahata T, Shao W, Endoh H, Hur J, Coser KR, Sun H, Ueda Y, Kato S,
Isselbacher KJ, Brown M, et al. (2001). Selective coactivation of
estrogen-dependent transcription by CITED1 CBP/p300–binding pro-
tein. Genes Dev 15, 2598–2612.
[44] Jepsen P, Olsen ML, Mellemkjaer L, Olsen JH, and Sorensen HT
(2004). A registry-based study of gender, fetal growth, and risk of Wilms
tumor. Pediatr Hematol Oncol 21, 435–439.
600 CITED1 Expression in Wilms’ Tumor Lovvorn et al.
Neoplasia . Vol. 9, No. 7, 2007
